Isomorphic Labs raises $5 billion to push its AI-designed drugs towards clinical trials
Greenoaks and Sequoia Capital co-led the Series C, with a16z and Alphabet also investing. Demis Hassabis says the money will fund biology models, disease research and the first programmes heading to the clinic.
Isomorphic Labs, the London drug discovery company spun out of Google DeepMind’s AlphaFold work, has raised $5 billion in a Series C round. Chief executive Demis Hassabis announced it on X on Tuesday morning, calling it funding “to accelerate our mission to Solve All Disease”.
Who is investing
The company’s announcement says the oversubscribed round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz (a16z) and several other new investors, with “continued significant investment” from Alphabet. All existing investors took part again: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose a valuation.
Background
Earlier stories on this thread.
What happened next
No later story on this thread is on the site yet. The archive is where later files land.
What the money is for
According to the news release, Isomorphic is scaling its drug design engine, called IsoDDE, which combines a set of simulation models that work across several therapeutic areas and drug types. The company says the work is producing positive preclinical results in its own oncology and immunology programmes and with partners, “setting the stage for clinical entry”.
The proceeds will fund more advanced biology models, a partner network for research into how diseases work, computing infrastructure, and translational and clinical development as candidates move towards trials. Hassabis said the round lets the company drive “our first therapeutic programs towards clinical trials”.
Our read
Analysis: the size of the round is striking for a company that has not yet put a drug into human trials. Every efficacy claim so far is the company’s own description of preclinical work. The real test is whether its first candidates enter and progress through clinical trials, and the release gives no timeline for that.
This report is not legal, financial, or health advice. See the disclaimer.
Primary sources
- Demis Hassabis on X: $5B in funding for Isomorphic Labs Demis Hassabis on X
- Isomorphic Labs announces Series C investment round Isomorphic Labs
- Isomorphic Labs announces $5 Billion Series C funding (news release, PDF) Isomorphic Labs